An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-Free Survival (PFS)
The period from randomization until disease progression, death or date of last contact.
Baseline, every 8 weeks up to Year 1, then every 12 weeks up to Year 2, and then every 6 months until tumor progression or death (up to Year 5)
No
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
3066K1-305
NCT00117598
May 2005
January 2011
Name | Location |
---|---|
Pfizer Investigational Site | Blendora, California 91740 |
Pfizer Investigational Site | Springfield, Illinois 62701-1014 |
Pfizer Investigational Site | Bronx, New York 10461 |
Pfizer Investigational Site | Houston, Texas 77030 |
Pfizer Investigational Site | Federal Way, Washington 98003 |
Pfizer Investigational Site | North Little Rock, Arkansas 72117 |
Pfizer Investigational Site | Clearwater, Florida 33761 |
Pfizer Investigational Site | Eugene, Oregon 97401 |
Pfizer Investigational Site | Kingston, Pennsylvania 18704-5535 |
Pfizer Investigational Site | Farmington, Connecticut 06030-3805 |
Pfizer Investigational Site | Livingston, New Jersey 07039 |
Pfizer Investigational Site | Washington, District of Columbia 20007-2197 |
Pfizer Investigational Site | Honolulu, Hawaii 96813 |